About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker IONS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 2, 2026A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Part…
NCT07727538 · Familial Chylomicronemia Syndrome
Olezarsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Recruiting12Aug 2030Registry ↗
Nov 2, 2026A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974 · Hypertriglyceridemia, Severe Hypertriglyceridemia
ION775
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Recruiting72Sep 2027Registry ↗
Nov 2, 2026ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
NCT07531745 · Dravet Syndrome
ION337
IONS
Ionis Pharmaceuticals, Inc.
Phase 1/2Recruiting32Dec 2030Registry ↗
Nov 2, 2026Donidalorsen Treatment in Children With Hereditary Angioedema
NCT07298447 · Hereditary Angioedema (HAE)
Donidalorsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Recruiting20Jun 2029Registry ↗
Nov 2, 2026Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Peliz…
NCT05659901 · Pelizaeus-Merzbacher Disease
IONS
Ionis Pharmaceuticals, Inc.
—Recruiting32Mar 2029Registry ↗
Oct 20, 2026CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adult…
NCT07782827 · Angelman Syndrome
obudanersen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Recruiting30May 2028Registry ↗
Oct 8, 2026ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Int…
NCT06430385 · Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
ION440, Sham procedure
IONS
Ionis Pharmaceuticals, Inc.
Phase 1/2Recruiting48Sep 2027Registry ↗
Sep 29, 2026Zilganersen Expanded Access Program for Individuals With Alexander Disease
NCT07487389 · Alexander Disease
zilganersen
IONS
Ionis Pharmaceuticals, Inc.
—Approved for marketing——Registry ↗
Sep 29, 2026REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
NCT06914609 · Angelman Syndrome
obudanersen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting156Aug 2027Registry ↗
Sep 18, 2026PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION…
NCT06153966 · Prion Disease
ION717, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 1/2Active, not recruiting85Apr 2027Registry ↗
Sep 14, 2026CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
NCT06073574 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Cardiac MRI
IONS
Ionis Pharmaceuticals, Inc.
—Completed160Mar 13, 2026Registry ↗
Sep 11, 2026The CARDIO-TTRansform Scintigraphy Sub-study
NCT06073587 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Scintigraphy scan
IONS
Ionis Pharmaceuticals, Inc.
—Completed163Mar 25, 2026Registry ↗
Sep 4, 2026Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema
NCT06415448 · Hereditary Angioedema
Donidalorsen
IONS
Ionis Pharmaceuticals, Inc.
—Approved for marketing——Registry ↗
Sep 3, 2026CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as IO…
NCT04136171 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Eplontersen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Completed1,438Mar 25, 2026Registry ↗
Aug 21, 2026A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Dise…
NCT04849741 · Alexander Disease
zilganersen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting54Aug 22, 2025Registry ↗
Aug 20, 2026HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Do…
NCT05127226 · Angelman Syndrome
ION582
IONS
Ionis Pharmaceuticals, Inc.
Phase 1/2Active, not recruiting71Mar 2029Registry ↗
Jul 29, 2026A Non-interventional Cohort Safety Study of Patients With hATTR-PN
NCT04850105 · Hereditary Transthyretin Amyloidosis With Polyneuropthy
Data Collection
IONS
Akcea Therapeutics
—Active, not recruiting202Mar 31, 2036Registry ↗
Jul 21, 2026FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 i…
NCT04768972 · Amyotrophic Lateral Sclerosis
ION363, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting89Jun 17, 2026Registry ↗
Jul 9, 2026A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycyth…
NCT05143957 · Phlebotomy Dependent Polycythemia Vera
sapablursen
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed50Jun 26, 2025Registry ↗
May 8, 2026An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
NCT04307381 · Hereditary Angioedema
Donidalorsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed20Jan 24, 2025Registry ↗
Apr 27, 2026Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults W…
NCT04165486 · Multiple System Atrophy
ION464, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 1Recruiting40Sep 2027Registry ↗
Apr 23, 2026A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and…
NCT05355402 · Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease
Olezarsen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed154Mar 22, 2023Registry ↗
Apr 17, 2026An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated…
NCT05667493 · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Eplontersen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Enrolling by invitation1,400Aug 2029Registry ↗
Apr 9, 2026Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl…
NCT06014541 · Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
IONS
Ionis Pharmaceuticals, Inc.
—Terminated29Oct 7, 2025Registry ↗
Feb 20, 2026Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics…
NCT06673069 · Alzheimer Disease, Down Syndrome
ION269
IONS
Ionis Pharmaceuticals, Inc.
Phase 1Terminated1Dec 3, 2025Registry ↗
Feb 10, 2026A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Ca…
NCT05610280 · Hypertriglyceridemia, Cardiovascular Diseases
Olezarsen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Completed1,478Aug 8, 2024Registry ↗
Feb 10, 2026A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
NCT05079919 · Severe Hypertriglyceridemia
Olezarsen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Completed617Oct 22, 2024Registry ↗
Dec 12, 2025Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecall…
NCT06150716 · Pelizaeus-Merzbacher Disease
ION356
IONS
Ionis Pharmaceuticals, Inc.
Phase 1Recruiting24Jun 2028Registry ↗
Dec 12, 2025A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment o…
NCT05392114 · Hereditary Angioedema
Donidalorsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting154Dec 2026Registry ↗
Dec 12, 2025A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chy…
NCT05185843 · Familial Chylomicronemia Syndrome
Olezarsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting24Jun 2027Registry ↗
Dec 12, 2025A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicro…
NCT05130450 · Familial Chylomicronemia Syndrome
Olezarsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting60Feb 2028Registry ↗
Dec 4, 2025A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, I…
NCT05071300 · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Eplontersen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting151Aug 2029Registry ↗
Dec 1, 2025CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Sever…
NCT05681351 · Severe Hypertriglyceridemia
Olezarsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Active, not recruiting885Mar 2027Registry ↗
Oct 22, 2025A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
NCT05552326 · Severe Hypertriglyceridemia
Olezarsen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Completed446Dec 17, 2024Registry ↗
Sep 23, 2025A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkin…
NCT03976349 · Parkinson's Disease
BIIB094, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 1Completed62Aug 12, 2024Registry ↗
Aug 19, 2025TEGSEDI Pregnancy Surveillance Program
NCT04270058 · Hereditary Transthyretin-mediated Amyloidosis With Polynero…
inotersen
IONS
Akcea Therapeutics
—Not yet recruiting20Nov 15, 2030Registry ↗
Apr 10, 2025A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult…
NCT04306510 · Hereditary Transthyretin Amyloidosis With Polyneuropthy
TEGSEDI
IONS
Akcea Therapeutics
Phase 4Terminated8Mar 20, 2024Registry ↗
Apr 8, 2025Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild…
NCT03186989 · Mild Alzheimer's Disease
IONIS MAPTRx, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 1Completed46May 12, 2022Registry ↗
Mar 7, 2025GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participan…
NCT03815825 · Macular Degeneration, Geographic Atrophy
IONIS-FB-LRx, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed332Apr 18, 2024Registry ↗
Mar 6, 2025OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LR…
NCT05139810 · Hereditary Angioedema
Donidalorsen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Completed91Nov 9, 2023Registry ↗
Mar 6, 2025A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial C…
NCT04568434 · Familial Chylomicronemia Syndrome
Olezarsen, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Completed66Jul 14, 2023Registry ↗
Feb 18, 2025A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participan…
NCT04714320 · Hypertension
Placebo, IONIS-AGT-LRx
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed160Jun 29, 2022Registry ↗
Feb 18, 2025Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sap…
NCT04059406 · Beta Thalassemia Intermedia
sapablursen
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Terminated29Mar 28, 2023Registry ↗
Jan 23, 2025A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complem…
NCT04014335 · Primary IgA Nephropathy
IONIS-FB-LRx
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed23Feb 8, 2024Registry ↗
Dec 27, 2024Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
NCT06360237 · Familial Chylomicronemia Syndrome
Olezarsen
IONS
Ionis Pharmaceuticals, Inc.
—Approved for marketing——Registry ↗
Dec 13, 2024NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION…
NCT04136184 · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Inotersen, Eplontersen
IONS
Ionis Pharmaceuticals, Inc.
Phase 3Completed168Apr 11, 2023Registry ↗
Nov 27, 2024A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224
NCT04932512 · Steatohepatitis, Nonalcoholic
ION224, Placebo
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed160Jan 10, 2024Registry ↗
Oct 31, 2024A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
NCT04398485 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
ION251
IONS
Ionis Pharmaceuticals, Inc.
Phase 1Completed23Sep 30, 2024Registry ↗
Oct 3, 2024A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients…
NCT04522180 · Acromegaly
GHR-LRX
IONS
Ionis Pharmaceuticals, Inc.
Phase 2Completed34Jul 15, 2022Registry ↗
May 10, 2024A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two…
NCT05579860 · Healthy Participants
Olezarsen
IONS
Ionis Pharmaceuticals, Inc.
Phase 1Completed104May 22, 2023Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:46 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances